- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07947095
Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms (CHIME)
Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms: Randomized Controlled Trial (CHIME Trial)
The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.
The main questions it aims to answer are:
- Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
- Are the positive effects of calisda already noticeable after three months?
Researchers will compare two groups:
- Intervention group: Participants use the calisda intervention and continue their usual treatment.
- Control group: Participants continue with their usual treatment only.
Participants will:
- Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
- Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of calisda, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, calisda incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.
After confirming eligibility, participants are randomly assigned to one of two groups. The intervention group receives immediate access to calisda for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.
Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the six-month follow-up. Data collected at the three-month mark will be utilized to assess early treatment response.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Anja Specht, MSc.
- Número de telefone: +49 40 3510520
- E-mail: anja.specht@gaia-group.com
Estude backup de contato
- Nome: Clara Ekerdt, PhD
- Número de telefone: +49 40 351052 135
- E-mail: clara.ekerdt@gaia-group.com
Locais de estudo
-
-
-
Hamburg, Alemanha
- GAIA AG
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female biological sex
- Age 40-65 years
- Diagnosis of menopause symptoms (ICD-10 code: N95.1) confirmed by a medical document
- Increased levels of menopause symptoms (MRS-II total score ≥ 14)
- Reduced menopause-specific quality of life (MENQOL total score ≥ 3)
- Stable symptom-related treatment (medication, psychotherapy, no treatment, …) for at least 60 days at the time of inclusion
- Sufficient knowledge of the German language
- Basic computer skills required for independent use of a digital intervention
- Consent to participation
Exclusion Criteria:
- Plans to change symptom-related treatment (medication, psychotherapy, …) in the upcoming 6 months after inclusion
- Current or history of any malignancy except for basal and squamous cell skin tumors
- Current HRT use
- Premature, medically induced menopause (e.g. following bilateral oophorectomy)
- Known somatic or psychiatric condition that might interfere with successful study participation (e.g. unstable neurologic or psychiatric disorder)
- Previous use of a digital intervention for menopause symptoms (including calisda) or another digital intervention developed by GAIA.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: calisda
Participants will receive access to the digital health intervention calisda in addition to TAU. |
Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU). calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months. |
|
Sem intervenção: Control group
Participants allocated to the control group will receive access to treatment as usual (TAU). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score
Prazo: 6 months
|
The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life. |
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hot Flash Related Daily Interference Scale (HFRDIS) total score
Prazo: 6 months
|
The HFRDIS is a 10-item PROM assessing the extent to which hot flashes interfere with daily activities and overall quality of life over the past week. Each item is rated from 0 ("did not interfere") to 10 ("completely interfere"). The total score is the mean of all items and ranges from 0 to 10. Higher total scores indicate greater hot flash interference and thus a worse outcome, whereas lower scores indicate less interference and a better outcome. |
6 months
|
|
Insomnia Severity Index (ISI) total score
Prazo: 6 months
|
The ISI is a 7-item PROM assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point scale from 0 to 4. The total score is the sum of all items and ranges from 0 to 28. Higher total scores indicate greater insomnia severity and thus a worse outcome, whereas lower scores indicate less insomnia severity and a better outcome. |
6 months
|
|
Patient Health Questionnaire (PHQ-9) total score
Prazo: 6 months
|
The PHQ-9 is a 9-item PROM assessing the severity of depressive symptoms. Each item is scored from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 27. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
|
Menopause Rating Scale II (MRS-II) total score
Prazo: 6 months
|
The MRS-II is an 11-item PROM assessing the severity of menopause-related symptoms. Each item is rated from 0 ("no complaints") to 4 ("very severe symptoms"). The total score is the sum of all items and ranges from 0 to 44. Higher total scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Philipp Klein, Prof. Dr. med., Universität zu Lübeck, Zentrum für Integrative Psychiatrie ZiP gGmbH
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- calisda RCT 2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .